Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
News & Media
Home
>
News & Media
>
Media
Media
Media
Filter by Year:
2025
2024
2023
15-May-2023
IRSF Parent Panel: My Trofinetide Clinical Trial Experience
20-Mar-2023
Proactive interview, 20 March 2023
14-Mar-2023
Ausbiz interview, 14 March 2023
13-Mar-2023
Finance News Network interview, 13 March 2023
10-Nov-2022
Neuren on Marcus Today Podcast, 7 Nov 2022
14-Sep-2022
Neuren Pharmaceuticals with Proactive at ASX Small and Mid-Cap Conference
24-Jun-2022
AusBiz interview 22 June 2022
4-Apr-2022
Australian Financial Review article 4 Apr 2022
10-Dec-2021
AusBiz interview 8 December 2021
2-Jul-2021
Peak TV interview 2 July 2021
Previous
1
2
3
Next
